NEW YORK — EliTech Group and InfanDx said on Wednesday that they have agreed to collaborate on a test for hypoxic-ischemic encephalopathy (HIE), a form of brain damage caused by lack of oxygen that can occur in newborns.
Under the terms of a memorandum of understanding, the companies will work together to develop and manufacture InfanDx's HypoxE HIE early detection test for use on EliTech's Selectra Pro near-patient clinical chemistry analyzers.
Cologne, Germany-based InfanDx will be responsible for assay design, verification, and validation, as well as submitting the test for CE-IVD marking. Prototype lots and the final product will be contract-manufactured by EliTech.
The companies said that the test will be commercialized under InfanDx's branding through a network of commercial partners, and that they are discussing a commercial arrangement under which Puteaux, France-based EliTech will distribute the product.
Additional terms of the deal were not disclosed.
Earlier this year, InfanDx said that it is targeting a 2023 European launch for HypoxE.